Investment
Features
FeesSafety
Academy
More
Pluang+

DTCC to launch tokenized securities trading by 2026 with major banks and Ripple Prime onboard

Market News
05 May 2026
Coinpaper
View Source
Bullish
pluang ai news

The Depository Trust & Clearing Corporation (DTCC) is advancing its tokenization service for securities, planning a phased rollout starting July 2026 and full launch by October 2026. This initiative involves over 50 major financial institutions, including BlackRock, JPMorgan, Goldman Sachs, Nasdaq, and Ripple Prime, aiming to integrate blockchain-based settlement into traditional capital markets. The service will enable tokenized equities, ETFs, and U.S. Treasuries to be processed within existing post-trade infrastructure, enhancing liquidity, transparency, and efficiency. This move marks a significant convergence between traditional finance and blockchain technology, signaling a shift towards regulated digital asset markets.

More News

Bankruptcy court approves $470M sale of Oceanwide Plaza, paving way for Downtown LA project completion before 2028 Olympics.

Bankruptcy court approves $470M sale of Oceanwide Plaza, paving way for Downtown LA project completion before 2028 Olympics.

The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...

Company Fundamentals
Bullish
1 hour ago
Axsome Therapeutics gets 'Outperform' rating on strong drug pipeline and FDA NDA acceptance for narcolepsy drug.

Axsome Therapeutics gets 'Outperform' rating on strong drug pipeline and FDA NDA acceptance for narcolepsy drug.

Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...

Analyst Insights
Bullish
3 hours ago
Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.

Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...

Company Fundamentals
Neutral
3 hours ago
Margin debt hits record $1.53T in June, up 7.9% from May and 51.5% year-over-year.

Margin debt hits record $1.53T in June, up 7.9% from May and 51.5% year-over-year.

Margin debt in the U.S. increased for the third consecutive month in June, reaching a record $1.53 trillion. This represents a 7.9% rise from May and a 51.5% increase compared to June last year. Adjusted for inflation, the growth remains significant ...

Market News
Neutral
4 hours ago
McDonald's stock falls 10.85% despite strong earnings and potential efficiency gains from automation.

McDonald's stock falls 10.85% despite strong earnings and potential efficiency gains from automation.

McDonald's stock has dropped 10.85% over the past year, underperforming the broader market which rose 18%. Despite this, McDonald's recently reported better-than-expected earnings with an 11% revenue increase, 12% rise in operating income, and 3.8% g...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App